Core Viewpoint - Fuhong Hanlin (02696) shares rose over 4% following the approval of its biosimilars BILDYOS and BILPREVDA by the UK Medicines and Healthcare products Regulatory Agency, which now cover all indications previously approved for the original drugs in the UK [1] Group 1: Company Developments - Fuhong Hanlin's stock increased by 4.53%, reaching HKD 64.6, with a trading volume of HKD 79.4842 million [1] - The UK regulatory approval allows Fuhong Hanlin to commercialize BILDYOS and BILPREVDA, which are part of a broader agreement with Organon for exclusive commercialization rights outside of China [1] Group 2: Investment Activity - Boyu Capital has increased its holdings in Fuhong Hanlin, purchasing 262,500 shares and 80,000 shares on November 6 and November 10, respectively, raising its stake from 5.84% to 7% [1] - Earlier in the year, on June 18, Boyu Capital had already invested HKD 21.2673 million to increase its stake from 4.89% to 5.15%, surpassing the 5% threshold for reporting [1]
港股异动 | 复宏汉霖(02696)现涨超4% 地舒单抗BILDYOS和BILPREVDA获英国批准上市